Literature DB >> 33230974

MicroRNA-99 family in cancer and immunity.

Joseph Eniafe1, Shuai Jiang1.   

Abstract

The microRNA (miR)-99 family comprising miR-99a, miR-99b, and miR-100 is an evolutionarily conserved family with existence dating prior to the bilaterians. Members are typically oncogenic in leukemia while their functional roles in other cancers alternate between that of a tumor suppressor and a tumor promoter. Targets of the miR-99 family rank in the lists of oncogenes and tumor suppressors, thereby illustrating the dual role of this miR family as oncogenic miRs (oncomiRs) and tumor suppressing miRs (TSmiRs) in different cellular contexts. In addition to their functional roles in cancers, miR-99 family is implicated in the modulation of macrophage inflammatory responses and T-cell subsets biology, thereby exerting critical roles in the maintenance of tissue homeostasis, establishment of peripheral tolerance as well as resolution of an inflammatory reaction. Here, we review emerging knowledge of this miR family and discuss remaining concerns linked to their activities. A better dissection of the functional roles of miR-99 family members in cancer and immunity will help in the development of novel miR-99-based therapeutics for the treatment of human cancer and immune-related diseases. This article is categorized under: RNA in Disease and Development > RNA in Disease.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  OncomiR; TSmiR; mTOR; miR-99 family

Mesh:

Substances:

Year:  2020        PMID: 33230974     DOI: 10.1002/wrna.1635

Source DB:  PubMed          Journal:  Wiley Interdiscip Rev RNA        ISSN: 1757-7004            Impact factor:   9.957


  7 in total

1.  The E6 and E7 proteins of beta3 human papillomavirus 49 can deregulate both cellular and extracellular vesicles-carried microRNAs.

Authors:  Maria Vincenza Chiantore; Marco Iuliano; Roberta Maria Mongiovì; Sankhadeep Dutta; Massimo Tommasino; Paola Di Bonito; Luisa Accardi; Giorgio Mangino; Giovanna Romeo
Journal:  Infect Agent Cancer       Date:  2022-06-15       Impact factor: 3.698

2.  Novel Combinatorial MicroRNA-Binding Sites in AAV Vectors Synergistically Diminish Antigen Presentation and Transgene Immunity for Efficient and Stable Transduction.

Authors:  Manish Muhuri; Wei Zhan; Yukiko Maeda; Jia Li; Anoushka Lotun; Jennifer Chen; Katelyn Sylvia; Ishani Dasgupta; Motahareh Arjomandnejad; Thomas Nixon; Allison M Keeler; Sangeetha Manokaran; Ran He; Qin Su; Phillip W L Tai; Guangping Gao
Journal:  Front Immunol       Date:  2021-04-28       Impact factor: 8.786

3.  Genome Instability-Related miRNAs Predict Survival, Immune Landscape, and Immunotherapy Responses in Gastric Cancer.

Authors:  Yaqiong Liu; Lin Cheng; Wei Huang; Xin Cheng; Weijun Peng; Dazun Shi
Journal:  J Immunol Res       Date:  2021-11-01       Impact factor: 4.818

4.  Value of Serum miRNA-96-5p and miRNA-99a-5p as Diagnostic Biomarkers for Hepatocellular Carcinoma.

Authors:  Amal F Gharib; Emad M Eed; Amany S Khalifa; Nermin Raafat; Somaia Shehab-Eldeen; Hany R Alwakeel; Ehab Darwiesh; Abdallah Essa
Journal:  Int J Gen Med       Date:  2022-03-03

5.  FBP1 /miR-24-1/enhancer axis activation blocks renal cell carcinoma progression via Warburg effect.

Authors:  Dongen Ju; Ying Liang; Guangdong Hou; Wanxiang Zheng; Geng Zhang; Xinlong Dun; Di Wei; Fei Yan; Lei Zhang; Dong Lai; Jiarui Yuan; Yu Zheng; Fuli Wang; Ping Meng; Yong Wang; Wenqiang Yu; Jianlin Yuan
Journal:  Front Oncol       Date:  2022-08-01       Impact factor: 5.738

6.  Identification of neoplasm-specific signatures of miRNA interactions by employing a systems biology approach.

Authors:  Reza Arshinchi Bonab; Seyedehsadaf Asfa; Panagiota Kontou; Gökhan Karakülah; Athanasia Pavlopoulou
Journal:  PeerJ       Date:  2022-10-03       Impact factor: 3.061

Review 7.  MicroRNA-1: Diverse role of a small player in multiple cancers.

Authors:  Parvez Khan; Nivetha Sarah Ebenezer; Jawed Akhtar Siddiqui; Shailendra Kumar Maurya; Imayavaramban Lakshmanan; Ravi Salgia; Surinder Kumar Batra; Mohd Wasim Nasser
Journal:  Semin Cell Dev Biol       Date:  2021-05-24       Impact factor: 7.727

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.